Adial Pharmaceuticals (ADIL)10% owner bought ~$4.6K

~$4.6K

Approx. value · 1,700 sh @ $2.70

385K

Holds after · shares reported

Traded

Jul 10, 2026

Filed

Jul 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 11, 2026Company filing · Form 8-K · ResultsReported its results
2. Jun 11, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and changed a top executive or board member (and 5 more items)“On June 11, 2026, upon closing of the Merger, each director of the Company immediately prior to the First Effective Time will receive cash payment of $30,000. Resignation of Director In connection with the Merger, effective as of the First Effective Time, Tony Goodman resigned as a Class I Director of the Company.”
3. Jun 29, 2026Insider · First insider buy since Sep 202310% owner purchased ~$65K of ADIL shares in the open market
4. Jul 9, 2026Insider10% owner purchased ~$28K of ADIL shares in the open market
5. Jul 10, 2026 · this disclosureInsider10% owner purchased ~$4.6K of ADIL shares in the open market

What came next

1. Jul 14, 2026Insider10% owner purchased ~$5.3K of ADIL shares in the open market
2. Jul 16, 2026Insider10% owner purchased ~$3.4K of ADIL shares in the open market
3. Aug 10, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“As of August 10, 2026, Adial Pharmaceuticals, Inc. (the “Company”) anticipates that the employment of its current President and Chief Executive Officer, Cary Claiborne, will be terminated effective promptly after the Company’s 2026 Annual Meeting of Stockholders (“the 2026 Annual Meeting”) if certain of the proposals being presented to stockholders are approved (the “Stockholder Approval”), and that Matthew…”
4. Aug 17, 2026Company filing · Form 8-K · ResultsReported its results
5. Aug 18, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On August 18, 2026, Adial Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the stockholders’ equity reported in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026, the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq…”
6. Aug 19, 2026Company filing · Form 8-K · Unregistered sharesSold new shares without registering them
7. Sep 16, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
8. Sep 17, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On September 17, 2026, Adial Pharmaceuticals, Inc. (the “Company”) convened its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Adial Pharmaceuticals

For Adial Pharmaceuticals, OQRO holds 4 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ADIL page.

Other recent filings by Coastlands Capital LP, 10% owner

• SEC Form 4 at Adial Pharmaceuticals (ADIL)Jul 17, 2026
• SEC Form 4 at Adial Pharmaceuticals (ADIL)Jul 17, 2026
• SEC Form 4 at Adial Pharmaceuticals (ADIL)Jul 13, 2026
• SEC Form 4 at Adial Pharmaceuticals (ADIL)Jul 1, 2026
• SEC Form 4 at Pasithea Therapeutics (KTTA)Jun 22, 2026

The full history of Coastlands Capital LP, 10% owner is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Adial Pharmaceuticals

• SEC Form 4Jul 17, 2026
• SEC Form 4Jul 17, 2026
• SEC Form 4Jul 13, 2026
• SEC Form 4Jul 1, 2026

Everything OQRO holds on this company is on its ADIL page.